Milestone shifts how global pharmaceutical manufacturers approach post-approval life cycle management for medicines.
Outcomes from an international pilot could set the new norm for regulatory convergence on post-approval manufacturing changes for medicines, according to the initiative’s lead European Medicines Agency (EMA).
The Collaborative Assessment Pilot evaluated use of a new recombinant endotoxins test as an alternative to the traditional limulus amebocyte lysate (LAL) test. This supports the industry’s commitment to reducing reliance on animal-derived materials, such as horseshoe crab blood.
The submission, structured as a Post-Approval Change Management Protocol (PACMP), includes changes such as adding a new manufacturing site, increasing production capacity, improving a manufacturing process, or updating testing methods.
The other regulatory partners are, under the International Coalition of Medicines Regulatory Authorities (ICMRA): the US Food and Drug Administration (FDA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA); Health Canada, Swissmedic and Australia’s Therapeutic Goods Administration (TGA).
Michael Kopcha, Director of the Office of Pharmaceutical Quality in FDA’s Center for Drug Evaluation and Research, noted that collaboration is key for knowledge-sharing and promoting innovation.
Following a standard 120-day review, the six major global regulators reached aligned decisions within days of each other, demonstrating how positive regulatory convergence can enable manufacturing modernisation.
If substantiated, this type of collaborative assessment could significantly reduce duplicated CMC review, meanwhile enhancing the predictability of regulation and aiding resilience of medicine supply.
The core challenge for technical leaders now moves directly to data governance”
Antonello Di Carlo, pharmaceutical legislation expert and independent consultant
Commenting on LinkedIn, pharmaceutical legislation expert and independent consultant, Antonello Di Carlo, added: “From an Operations and Quality Engineering standpoint, this convergence drastically reduces analytical variability and shortens industrial validation timelines. The core challenge for technical leaders now moves directly to data governance.
“Managing a single global submission across multiple jurisdictions requires flawless data integrity, comprehensive contamination control strategies (CCS) under Annex 1, and predictive process engineering parameters. This ICMRA pilot paves a clear, data-driven highway for pharmaceutical operations to innovate at scale without being held back by historic global documentation bottlenecks.”
No comments yet